Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

LeonaBio (LONA) Stock Price & Analysis

580 Followers

LONA Stock Chart & Stats

$4.77$0.04(0.85%)
At close: 4:00 PM EST
$2.5$5$7.5Aug 10Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2
Day’s Range
$4.69 - $4.90
52-Week Range
$2.21 - $14.21
Previous Close
$4.73
Volume
N/A
Average Volume (3M)
359.23K
Market Cap
$44.56M
Enterprise Value
$167.55M
Total Cash (Recent Filing)
$51.07M
Total Debt (Recent Filing)
$577.00K
Price to Earnings (P/E)
―
Beta
1.21
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
-0.69
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Financial Leverage

Very low debt relative to equity reduces solvency pressure and limits interest-related cash demands. This gives LeonaBio greater flexibility to direct available resources toward clinical development, although it does not offset the company’s current losses and ongoing need for funding.

Phase 3 Clinical Progress

Reaching a major enrollment milestone in the lead Phase 3 trial demonstrates continued execution in late-stage development and advances the program toward potentially important regulatory outcomes. Progress at this stage can strengthen the company’s strategic position if clinical and regulatory results remain supportive.

Potential Financing Capacity

The warrant exercise opportunity could materially strengthen liquidity and provide resources for ongoing clinical and strategic initiatives. If exercised for cash, the proceeds may extend funding capacity and reduce near-term financing pressure, though the capital is conditional rather than guaranteed.

Bears Say

Pre-revenue Operating Model

A continuing absence of revenue means LeonaBio has not yet demonstrated commercial demand or an operating revenue base to support its cost structure. Until a product generates sales, the company remains dependent on financing and clinical progress rather than internally funded operations.

Worsening Losses

The widening net loss indicates that spending and operating demands are increasing faster than the company’s ability to generate income. Persistent deterioration raises the amount of capital required to reach commercialization and reduces evidence of near-term operating leverage or profitability.

Persistent Cash Burn And Declining Equity

Negative operating cash flow shows that the business is consuming cash rather than funding itself, while the large decline in equity reflects substantial capital usage and accumulated losses. This combination increases dependence on external financing and creates continuing dilution and funding risks.

LeonaBio News

LONA FAQ

What was LeonaBio’s price range in the past 12 months?
LeonaBio lowest stock price was $2.21 and its highest was $14.21 in the past 12 months.
What is LeonaBio’s market cap?
LeonaBio’s market cap is $44.56M.
When is LeonaBio’s upcoming earnings report date?
LeonaBio’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 1 day.
How were LeonaBio’s earnings last quarter?
LeonaBio released its earnings results on Aug 14, 2026. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$1.389 by $0.589.
Is LeonaBio overvalued?
According to Wall Street analysts LeonaBio’s price is currently Undervalued.
Does LeonaBio pay dividends?
LeonaBio does not currently pay dividends.
What is LeonaBio’s EPS estimate?
LeonaBio’s EPS estimate is -0.69.
How many shares outstanding does LeonaBio have?
LeonaBio has 9,421,663 shares outstanding.
What happened to LeonaBio’s price movement after its last earnings report?
LeonaBio reported an EPS of -$0.8 in its last earnings report, beating expectations of -$1.389. Following the earnings report the stock price went down -3.202%.
Which hedge fund is a major shareholder of LeonaBio?
Hedge funds hold LeonaBio shares: the largest hedge-fund position in LeonaBio is 70,140,608 shares, and hedge funds increased their holdings by 347.8K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology